Robert Croop

2.9k total citations · 4 hit papers
106 papers, 2.0k citations indexed

About

Robert Croop is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Sensory Systems. According to data from OpenAlex, Robert Croop has authored 106 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Psychiatry and Mental health, 19 papers in Pathology and Forensic Medicine and 19 papers in Sensory Systems. Recurrent topics in Robert Croop's work include Migraine and Headache Studies (82 papers), Olfactory and Sensory Function Studies (19 papers) and Trigeminal Neuralgia and Treatments (16 papers). Robert Croop is often cited by papers focused on Migraine and Headache Studies (82 papers), Olfactory and Sensory Function Studies (19 papers) and Trigeminal Neuralgia and Treatments (16 papers). Robert Croop collaborates with scholars based in United States, United Kingdom and Canada. Robert Croop's co-authors include Vladimir Coric, Richard B. Lipton, Charles M. Conway, David Stock, Peter J. Goadsby, Elyse Stock, Micaela Forshaw, David Kudrow, Alexandra Thiry and Beth Morris and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Robert Croop

95 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

2019 276 citations Robert Croop, Peter J. Goadsby et al. The Lancet profile →
Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

2019 265 citations Richard B. Lipton, Robert Croop et al. profile →
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

2020 233 citations Robert Croop, Richard B. Lipton et al. The Lancet profile →
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial

2023 85 citations Richard B. Lipton, Robert Croop et al. profile →

Peers

Countries citing papers authored by Robert Croop

Since Specialization

Citations

This map shows the geographic impact of Robert Croop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Croop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Croop more than expected).

Fields of papers citing papers by Robert Croop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Croop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Croop. The network helps show where Robert Croop may publish in the future.

Co-authorship network of co-authors of Robert Croop

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Croop. A scholar is included among the top collaborators of Robert Croop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Croop. Robert Croop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double‐blind, randomized controlled trial 2025 ·Headache The Journal of Head and Face Pain ·(unknown), Yasuhiko Matsumori, (unknown), Tomofumi Ishikawa, (unknown), Hiroki‎ Yoshimatsu, Alexandra Thiry, (unknown), Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima	3
2	Plain Language Summary Publication: Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double‐blind, randomized controlled trial 2025 ·Headache The Journal of Head and Face Pain ·(unknown), Yasuhiko Matsumori, (unknown), Tomofumi Ishikawa, (unknown), Hiroki‎ Yoshimatsu, Alexandra Thiry, (unknown), Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima	0
3	Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial 2025 ·Headache The Journal of Head and Face Pain ·Koichi Ikeda, Yasuhiko Matsumori, Masako Kudo, Tomofumi Ishikawa, Yuko Hoshino, Hiroki‎ Yoshimatsu, Alexandra Thiry, (unknown), Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima	2
4	A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine 2025 ·Headache The Journal of Head and Face Pain ·David Kudrow, Robert Croop, Alexandra Thiry, Richard Lipton	4
5	Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial 2024 ·Journal of Pain Research ·Richard B. Lipton, Alexandra Thiry, (unknown), Robert Croop	14
6	Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment 2024 ·Clinical and Translational Science ·Rajinder Bhardwaj, (unknown), Jennifer Madonia, Beth Morris, Thomas Marbury, Kyle Matschke, Robert Croop, Richard Bertz, (unknown)	4
7	Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study 2024 ·Cephalalgia ·Kathleen Mullin, Robert Croop, (unknown), Terence Fullerton, Jennifer Madonia, Richard B. Lipton	5
8	A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine 2024 ·Cephalalgia ·Robert Croop, Gary Berman, David Kudrow, Kathleen Mullin, Alexandra Thiry, Meghan Lovegren, Gilbert L’Italien, Richard B. Lipton	22
9	Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects 2024 ·Clinical and Translational Science ·Rajinder Bhardwaj, (unknown), Jennifer Madonia, Matt S. Anderson, Kyle Matschke, Richard Bertz, Robert Croop, (unknown)	4
10	Deconvoluting zavegepant drug–drug interactions: A phase I study to evaluate the effects of rifampin and itraconazole on zavegepant pharmacokinetics 2024 ·Clinical and Translational Science ·Rajinder Bhardwaj, (unknown), Jennifer Madonia, Matt S. Anderson, Beth Morris, Kyle Matschke, Robert Croop, Richard Bertz, (unknown)	1
11	No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults 2024 ·Clinical and Translational Science ·Rajinder Bhardwaj, (unknown), Beth Morris, Kyle Matschke, Richard Bertz, Robert Croop, (unknown)	3
12	Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study 2024 ·Pain and Therapy ·(unknown), Kathleen Mullin, Robert Croop	10
13	Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial 2024 ·The Journal of Headache and Pain ·Shengyuan Yu, (unknown), Zhen Wang, (unknown), Ge Tan, Qian Yang, Mingjie Zhang, (unknown), Dawei Chen, Yongbo Zhang, Robert Croop, Yanhui Sun, Yu Liu, (unknown), Zhihong Lu	4
14	POSC202 Estimated Migraine Patient Population in England Progressing Beyond First-Line Acute Management 2022 ·Value in Health ·Linda Harris, Gilbert L’Italien, Robert Croop, Vladimir Coric, James M. Robbins, (unknown), (unknown)	1
15	Acute Treatment with Rimegepant 75 mg Confers Long Term Improvements in Median Time to 30% and 50% Reductions in Monthly Migraine Days – Post Hoc Results from an Open Label Safety Study (BHVN-3000-201) (4737) 2021 ·Neurology ·Gilbert L’Italien, Evan Popoff, (unknown), Linda Harris, Karissa Johnston, Robert Croop, Vlad Coric	1
16	Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials (2091) 2020 ·Neurology ·Jelena Pavlović, David W. Dodick, Lawrence C. Newman, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charles M. Conway, (unknown), Beth Morris, Vladimir Coric, Robert Croop	1
17	Cardiovascular Safety of Rimegepant 75 mg in 3 Randomized Clinical Trials and Systematic Evaluations from In Vitro, Ex Vivo, and In Vivo Nonclinical Assays (2141) 2020 ·Neurology ·Charles M. Conway, Robert Croop, Gene M. Dubowchik, Vladimir Coric, Richard B. Lipton	12
18	Rimegepant Has No Clinically Relevant Effect on ECG parameters at Therapeutic and Supratherapeutic Doses: A Thorough QT Study Versus Placebo and Moxifloxacin in Healthy Subjects (2117) 2020 ·Neurology ·Michael Hanna, Vladimir Coric, Joseph Stringfellow, (unknown), Robert Croop	2
19	Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial breakdown → 2019 ·The Lancet ·Robert Croop, Peter J. Goadsby, David Stock, Charles M. Conway, Micaela Forshaw, Elyse Stock, Vladimir Coric, Richard B. Lipton	276
20	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral γ-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers 2012 ·Clinical Therapeutics ·Gary Tong, Junsheng Wang, Oleksandr Sverdlov, Shu‐Pang Huang, Randy Slemmon, Robert Croop, (unknown), Huidong Gu, Oi T. Wong, Hewei Li, Robert Berman, (unknown), Charles F. Albright, Randy Dockens	54

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact